Metagenomi Therapeutics, Inc.
MGX
Last
$1.00
Day
+0.7%
1y
-68.3%
5y
-90.4%
52w
-74.9%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-1030d
EMA 21
1.08
EMA 50
1.14
EMA 200
1.40
20d high
-16.9%
5y high
-92.2%
5y range
0th
Positions held
Your positionsMGX isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-24
Hold
avoid
Signal
Strong Sell
Target
$1.09
Stop
$0.91
Stop distance
9.0%
Target vs last
+9.0%
Fundamentals
| Market cap | $37.52M | Enterprise value | -$45.42M | Trailing P/E | — | Forward P/E | -0.54 |
| PEG | — | Price / book | 0.33 | Beta | 0.70 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 112.0% |
| Profit margin | 0.0% | ROE | -60.6% | ROA | -28.2% | Debt / equity | 0.34 |
| Current ratio | 4.50 | Free cash flow | -$50.95M | Analyst recommendation | strong_buy | Mean target | $7.00 |
| 52w high | $3.95 | 52w low | $0.96 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | -$0.3M | $1.2M | $3.9M | $8.7M | $8.5M | — |
| Op margin | 11195.7% | -1970.1% | -623.0% | -263.8% | -246.5% | — |
| Net income | -$27.5M | -$23.1M | -$22.5M | -$20.4M | -$19.9M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$28.8M | -$24.6M | -$24.4M | -$22.8M | -$21.0M | — |
- Revenue -121% vs prior quarter (-$0.3M vs $1.2M).
- Operating margin expanded to 11195.7%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $25.2M | $52.3M | $44.8M | $17.2M | — |
| Op margin | -380.9% | -170.0% | -175.4% | -259.5% | — |
| Net income | -$87.9M | -$78.1M | -$68.3M | -$43.6M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$96.0M | -$88.9M | -$78.5M | -$44.6M | — |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-01 · Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference
2026-08-10 · Metagenomi Therapeutics (MGX) Reports Q2 Loss, Lags Revenue Estimates
2026-08-10 · Metagenomi Therapeutics: Q2 Earnings Snapshot
2026-08-10 · Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
Price (daily)
Full chart · RSI · MACD · patternsMGX · daily-12.9% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin